Halozyme Therapeutics, Inc. (HALO) shares up after passing $1 billion in revenue for first time, strong guidance.
Oil prices extended their gains on Tuesday after threats by U.S. President Donald Trump to impose secondary tariffs on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback